News

Drugmaker Novo Nordisk freezes hiring for non-critical jobs

Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...
ConsumerAffairs9h

GoodRx teams up with Novo Nordisk to make weight loss drugs more affordable

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

Novo Nordisk to sell weight-loss drug for $499 to eligible customers

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Novo Nordisk slashes price of Ozempic to $499 for cash-paying, uninsured patients

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Stocks to Watch Monday: Novo Nordisk, TeraWulf, UnitedHealth, Soho House

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease.

Novo Nordisk A/S: Novo Nordisk to present Wegovy and Ozempic data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European ...

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation - a common heart rhythm condition - in people living with obesity (SELECT study)Additional Rybelsus® and Ozempic® da ...
BioSpace1d

Oral Wegovy’s Pending Approval Puts Spotlight on Viability of High-Dose Peptides

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...

GoodRx Stock Spikes 35% on Novo Nordisk Collaboration. They’re Offering Ozempic for $499 a Month.

Shares of GoodRx were spiking 35% on Monday. The announcement followed news from Novo Nordisk that the Food and Drug ...